Predictive value of serum uric acid on readmission of acute coronary syndrome patients within 6 months after treatment
Received:June 19, 2022  
View Full Text  View/Add Comment  Download reader
Key words:serum uric acid  acute coronary syndrome  readmission  risk factors This work was supported by the Project for Clinical Medical Research Center of Hainan Science and Technology Plan
Author NameAffiliationE-mail
LI Dong-Yun First Departmen of Healthcare, Second Medical Center, Chinese PLA General Hospital, Beijing 100853, China likesxcn@163.compredictive 
LIN Ying Department of Cardiology, Hainan Province, China likesxcn@163.compredictive 
DONG Wen-Jing Department of Geriatrics, Hainan Province, China likesxcn@163.compredictive 
HU Ya-Lei Department of Hematology, Chinese PLA General Hospital Hainan Hospital, Sanya 572013, Hainan Province, China likesxcn@163.compredictive 
LI Ke Department of Cardiology, Hainan Province, China likesxcn@163.compredictive 
Hits: 44
Download times: 34
      Objective To investigate the association of serum uric acid (SUA) with readmission within 6 months after treatment in patients with acute coronary syndrome (ACS), and to investigate the predictive value of SUA for readmission within 6 months. Methods A retrospective cohort trial was carried out on the ACS patients hospitalized in Department of Cardiology of Chinese PLA General Hospital Hainan Hospital from January 2016 to March 2019. Univariate and binary logistic regression analyses were used to explore the related risk factors of readmission within 6 months after treatment. Receiver operating characteristic (ROC) curve was drawn to analyze the predictive performance of SUA for readmission. SAS9.4 and R4.0.3 were used for statistical analysis. Data comparison between two groups was perfomed using t test, Mann-Whitney U test, χ2 test or Bonferroni test depending on data type. Results A total of 462 patients were included in this study, and 47 of them were finally assigned into the readmission group and 415 into the non-readmission group in 6 months after treatment. Univariate analysis showed statistical significance in treatment method between the 2 groups (P<0.05). The patients from the readmission group had obviously higher SUA level (394.77±106.29 vs 346.17±91.58 μmol/L), larger ratios of hypertension [34 (72.34%) vs 231 cases (55.66%)], arthrolithiasis [13 (27.66%) vs 18 cases (4.34%)], and higher incidence of adverse events during hospitalization [12 (14.46%) vs 16 cases (3.86%)], but lower estimated glomerular filtration rate [1.04 (72.01,106.02) vs 92.98 (78.76,106.62) ml/(min·1.73 m2)] and proportion of statin use [36 (76.60%) vs 372 cases (89.64%)] when compared with those of the non-readmission group (all P<0.05). Multivariate analysis indicated that SUA level (OR =1.004,95%CI 1.001-1.006), treatment method (OR=5.027,95%CI 2.855-8.853) and adverse events during hospitalization (OR=0.144, 95%CI 0.050-0.410) were closely associated with readmission within 6 months after discharge (all P<0.05). The higher the SUA level was, the higher proportion of readmission in the ACS patients, and the area under the ROC curve of SUA for readmission was 0.649. Conclusion Elevated SUA level increases the risk of readmission within 6 months after discharge in ACS patients and has predictive value for the risk.